Team 17: (J. Guillermet-Guibert): to identify the role of PI3K isoforms in cancerogenesis
PI 3-kinases (PI3Ks) are key signal transduction enzymes which are generally considered to be excellent new targets for therapeutic interference. Mammals have multiple PI3K isoforms, each of them having a specific physiological role.
While global PI3K inhibitors are already tested in clinical trials for cancer applications, the implication of the different isoforms of PI3K in cancer is still unclear and intensely debated. Our aim is to increase the understanding of the complex relationship within the different isoforms of PI3K in cancer cell signalling in vivo, in order to better target and prevent secondary effects in this clinical context.
We focus our attention on two lethal pathologies with no treatment, pancreatic and ovarian cancers.
We study the isoform-specific role of the signalling enzymes PI3Ks using new unique mouse models in which each isoform of PI3K is genetically inactivated, or genetic inactivation human primary culture using gene therapy.
Team 17's research projects are funded and have received support from: